Delcath Systems Stock Price. Everything You Need To Know About The Delcath Systems Stock!
Delcath Systems, Inc. is a New York City-based oncology company that focuses on treating primary and metastatic liver cancers. With 52 full-time employees and an IPO on 19th October 2000, the firm’s lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is a drug/device combination product designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
In Europe, Delcath Systems, Inc.’s commercial product, CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), is a medical device with the same device components as the HEPZATO KIT but without the melphalan hydrochloride. The product is designated as a Class III medical device and is being used in various medical centers to treat a range of liver cancers. On the other hand, in the United States, HEPZATO KIT is considered a combination drug and device product that administers concentrated regional chemotherapy to the liver.
Researching Delcath Systems, Inc.’s products and services can help you stay informed about the latest treatments for liver cancers. While we cannot provide investment advice, keeping an eye on the company’s growth trajectory and stock price is essential for making informed decisions.
Delcath Systems Stock Price. Everything You Need To Know About The Delcath Systems Stock! performance
- Employees 52
- Company HQ New York City
- Website http://delcath.com/
- DCTH Asset Type Common Stock
- DCTH Market Capitalization 132.5M
- Earnings Per Share -2.94
- Dividends Per Share None
- Dividend Date 2019-12-24
- Quarterly Earnings Growth 0
Delcath Systems is a cutting-edge biomedical technology company that focuses on the development of innovative, minimally invasive therapies for the treatment of liver cancers. The company’s flagship product, the Delcath Hepatic Delivery System (PHP), is designed to efficiently deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. This targeted approach ensures maximum treatment efficacy with fewer side effects. For retail investors from Malaysia, Thailand, Indonesia, and Vietnam, investing in Delcath Systems can be a promising opportunity to participate in the rapidly evolving field of cancer treatment. As the demand for advanced oncology solutions continues to grow, Delcath’s groundbreaking technology has the potential to gain significant market traction. To invest in Delcath Systems from these countries, interested investors can turn to Zorion’s investment platform. Zorion provides a user-friendly interface that enables retail investors to access real US stocks and pre-IPO companies, including Delcath Systems. Additionally, Zorion offers valuable investment insights and recommendations to help investors make informed decisions. By investing in Delcath Systems through Zorion, retail investors can diversify their investment portfolio and potentially capitalize on the growing demand for innovative cancer treatments. With access to educational resources and materials provided by Zorion, investors can enhance their investment knowledge and navigate the intricacies of the stock market more effectively. Investing in Delcath Systems presents an exciting opportunity for retail investors from Malaysia, Thailand, Indonesia, and Vietnam to support the advancement of cancer treatment while potentially reaping financial rewards. With Zorion’s comprehensive platform and expert guidance, investing in this stock has never been easier.
